Lenvatinib plus pembrolizumab resulted in antitumor activity in patients with metastatic clear cell RCC that progressed during or after treatment with an immune checkpoint inhibitor, according to phase 2 results.
Tivozanib resulted in superior PFS compared with sorafenib among patients with RCC that progressed on 2 or 3 prior systemic regimens, including another VEGF inhibitor, according to the final analysis of the TIVO-3 trial.
The phase 3 PROSPER RCC trial will evaluate neoadjuvant with adjuvant nivolumab among patients with nonmetastatic RCC compared with surgery and standard-of-care surveillance.
The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to results of a phase 2 trial.
A HIF-2α inhibitor demonstrated antitumor activity against VHL-associated clear cell RCC and other associated tumors, according to interim results of a phase 2 study.
Preliminary phase 2 data suggest that nivolumab plus ipilimumab was efficacious in advanced RCC that previously progressed with immune checkpoint inhibitor therapy.
